Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) CEO Mark C. Mckenna sold 25,000 shares of the stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $118.99, for a total value of $2,974,750.00. Following the transaction, the chief executive officer now directly owns 55,144 shares in the company, valued at approximately $6,561,584.56. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Prometheus Biosciences Price Performance

Shares of RXDX stock opened at $115.00 on Friday. The stock has a 50 day moving average of $87.83 and a two-hundred day moving average of $61.97. The company has a current ratio of 11.19, a quick ratio of 11.19 and a debt-to-equity ratio of 0.11. Prometheus Biosciences, Inc. has a 12 month low of $21.50 and a 12 month high of $122.75. The company has a market capitalization of $4.82 billion, a P/E ratio of -34.33 and a beta of -0.48.

Prometheus Biosciences (NASDAQ:RXDX – Get Rating) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.01). Prometheus Biosciences had a negative return on equity of 61.37% and a negative net margin of 1,847.71%. The firm had revenue of $0.97 million during the quarter, compared to the consensus estimate of $0.77 million. As a group, equities analysts expect that Prometheus Biosciences, Inc. will post -3.43 EPS for the current year.

Hedge Funds Weigh In On Prometheus Biosciences

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Royal Bank of Canada increased their price objective on Prometheus Biosciences from $66.00 to $111.00 in a report on Wednesday, December 7th. Wells Fargo & Company increased their target price on Prometheus Biosciences from $71.00 to $164.00 in a research note on Thursday, December 8th. BTIG Research increased their target price on Prometheus Biosciences from $74.00 to $181.00 and gave the company a "buy" rating in a research note on Thursday, December 8th. Oppenheimer increased their target price on Prometheus Biosciences from $61.00 to $125.00 and gave the company an "outperform" rating in a research note on Thursday, December 8th. Finally, Stifel Nicolaus increased their target price on Prometheus Biosciences from $50.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday, November 1st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Prometheus Biosciences currently has a consensus rating of "Buy" and an average price target of $107.80.

Prometheus Biosciences Company Profile

(Get Rating)

Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.

Recommended Stories

• Get a free copy of the StockNews.com research report on Prometheus Biosciences (RXDX)
• MarketBeat Week in Review – 1/16 – 1/20
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.